BIOMAT Database Logo BIOMAT Database Logo

Cidofovir added to highly active antiretroviral therapy in AIDS-associated progressive multifocal leukoencephalopathy. 2001

M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Infectious Diseases Service, University Hospital Virgen del Rocío, Seville, Spain.

UI MeSH Term Description Entries
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D008297 Male Males
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077404 Cidofovir An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS. 1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine,1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine,Cidofovir Anhydrous,Cidofovir Sodium,Cidofovir, (+-)-isomer,Cidofovir, (R)-isomer,Cidofovir, Sodium Salt,GS 504,GS-504,HPMPC,Vistide,GS504
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy.
December 1998, AIDS (London, England),
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy.
November 2001, Mayo Clinic proceedings,
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy.
March 1999, Neurology,
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy.
August 1999, Journal of neurology,
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy.
September 1998, The New England journal of medicine,
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy.
March 1998, AIDS (London, England),
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.
September 2000, AIDS (London, England),
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy.
October 1998, AIDS (London, England),
M Herrero-Romero, and E Cordero, and L F López-Cortés, and A de Alarcón, and J Pachón
Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy.
September 1998, AIDS (London, England),
Copied contents to your clipboard!